Physician profile
Ziaullah Virk
NPI 1740267533
$5,251.66
in general payments reported to CMS, 2019-2025
36 companies · $650 in 2025
The $650 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,791 · 2020: $102 · 2021: $165 · 2022: $754 · 2023: $221 · 2024: $570 · 2025: $650.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,340 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,340.12 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $1,342.76 | 2019 | |
| Amgen INC. | $861.56 | 2019-2025 | Evenity, Tavneos, Prolia |
| Ucb, INC. | $390.51 | 2019-2025 | Bimzelx |
| Janssen Biotech, INC. | $275.51 | 2019-2025 | Tremfya, Simponi Aria |
| Pfizer INC. | $243.22 | 2019-2025 | |
| Mallinckrodt Hospital Products INC. | $228.50 | 2020-2025 | Acthar |
| Abbvie INC. | $195.74 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $174.31 | 2019-2025 | |
| Glaxosmithkline, LLC. | $167.58 | 2019-2024 | Benlysta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $151.81 | 2019-2023 | Spiriva Respimat, Stiolto Respimat, Ofev |
| Corcept Therapeutics | $129.67 | 2022-2024 | Korlym |
| Boston Scientific Corporation | $128.62 | 2025 | Avvigo Guidance System |
| Genentech USA, INC. | $110.55 | 2019 | |
| Alexion Pharmaceuticals, INC. | $95.77 | 2019-2025 | Strensiq |
| Lilly USA, LLC | $86.69 | 2019-2024 | Taltz |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $63.39 | 2019 | |
| Medexus Pharma, INC. | $60.08 | 2019 | |
| Mallinckrodt Enterprises LLC | $57.49 | 2019 | |
| La Jolla Pharmaceutical Company | $48.02 | 2021-2022 | |
| Sobi, INC | $45.37 | 2019-2020 | |
| Melinta Therapeutics, LLC | $44.74 | 2019-2022 | |
| Actelion Pharmaceuticals US, INC. | $41.71 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $37.58 | 2022-2023 | Glassia |
| Abbott Laboratories | $33.05 | 2023 | Freestyle Libre 3 |
| Biogen, INC. | $32.91 | 2022-2023 | Vumerity |
| Astrazeneca Pharmaceuticals LP | $28.32 | 2021-2025 | Saphnelo |
| E.R. Squibb & Sons, L.L.C. | $28.16 | 2019-2021 | |
| Coloplast Corp | $22.68 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $19.87 | 2025 | Caplyta |
| Kowa Pharmaceuticals America, INC. | $17.27 | 2025 | Zoryve |
| Daiichi Sankyo INC. | $17.15 | 2022 | |
| Antares Pharma, INC. | $16.25 | 2019 | |
| Gilead Sciences, INC. | $15.40 | 2021 | |
| Shionogi INC | $14.31 | 2021 | |
| Merck Sharp & Dohme LLC | $14.23 | 2022 | |
| Horizon Therapeutics Plc | $10.88 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ziaullah Virk listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.